- Open Access
Hydrogen sulfide provides cardioprotection against myocardial/ischemia reperfusion injury in the diabetic state through the activation of the RISK pathway
© Lambert et al.; licensee BioMed Central Ltd. 2014
- Received: 3 September 2014
- Accepted: 25 November 2014
- Published: 12 December 2014
Coronary artery disease remains the principal cause of death in patients with diabetes mellitus. Diabetic mice display exacerbated injury following myocardial ischemia-reperfusion (MI/R) and are resistant to most therapeutic interventions. We have reported that sodium sulfide (Na2S) therapy confers cardioprotection during MI/R in non-diabetic mice. Here we tested the hypothesis that Na2S therapy would limit the extent of myocardial injury following MI/R when administered at the time of reperfusion.
Methods and results
Diabetic mice (db/db, 12 weeks of age) were subjected to transient myocardial ischemia for a period of 30 minutes followed by reperfusion up to 24 hours. Na2S (0.05 to 1 mg/kg) or saline (vehicle) was administered into the left ventricular lumen at the time of reperfusion. Na2S therapy significantly decreased myocardial injury in the db/db diabetic mouse, as evidenced by a reduction in infarct size and circulating troponin-I levels. The reduction in myocardial injury was also associated with a reduction in oxidative stress and a decrease in cleaved caspase-3 expression. In an effort to evaluate the signaling mechanism responsible for the observed cardioprotection, additional groups of mice were sacrificed during early reperfusion. Hearts were excised and processed for Western blot analysis. These studies revealed that Na2S therapy activated the Erk1/2 arm of the Reperfusion Injury Salvage Kinase (RISK) pathway.
These findings provide important information that myocardial Erk1/2 activation by Na2S therapy following MI/R sets into motion events, which ultimately lead to cardioprotection in the setting of diabetes.
- Hydrogen sulfide
- RISK pathway
- Myocardial Ischemia-reperfusion injury
Diabetes mellitus is a disease of metabolic dysregulation characterized by abnormal glucose metabolism . It is associated with a number of long-term complications associated with a decreased quality of life and reduced life expectancy including nephropathy, retinopathy, stroke and cardiovascular disease. For instance, patients with Type 2 diabetes mellitus (T2DM) have up to a 4-fold increased risk of developing coronary heart disease compared to non-diabetic patients. Moreover, patients with T2DM have a higher risk of mortality following myocardial ischemia compared with non-diabetics  due in part to an increased size of myocardial infarction . Therefore, it is critically important to develop and implement therapeutic strategies that will attenuate myocardial infarct size in T2DM patients. However, limited basic science research has been performed in the field of acute myocardial infarction in diabetic models as the large majority of research studies investigating myocardial ischemia-reperfusion (MI/R) injury have focused on otherwise healthy animals. Moreover, of the studies that have investigated the pathophysiology of MI/R injury in diabetes the majority have predominately used Type 1 diabetic models. This is an important observation given that T2DM encompasses roughly 90% of diabetic patients . As such, there is a paucity of research investigating the mechanisms of increased myocardial infarction in the setting of T2DM.
Hydrogen sulfide (H2S) is an endogenously produced gaseous signaling molecule that is critical for the regulation of cardiovascular homeostasis ,. It is produced enzymatically in mammalian species via the action of three enzymes in the cysteine biosynthesis pathway: cystathionine-γ-lyase (CSE), cystathionine-β-synthase (CBS), and 3-mercaptopyruvate sulfutransferase (3-MST). Over the last several years, several labs including ours have investigated the therapeutic potential of H2S. These studies provide compelling evidence that both exogenous and endogenous H2S exert cytoprotective effects, especially against MI/R injury and heart failure -. These and other studies demonstrate that H2S utilizes a variety of effects to counter ischemic injury, including its ability to attenuate oxidative stress, inhibit apoptosis, and reduce inflammation . Together, these findings suggest that therapy targeting endogenous and exogenous H2S offer cytoprotection against MI/R injury.
Recently, a role for H2S in the etiology of diabetes has been suggested . More specifically, circulating levels of H2S are negatively related to diabetes. For instance, plasma H2S levels decline in response to streptozotocin . Similarly, plasma H2S levels, as well as the aortic production of H2S progressively decrease as the diabetic pathology increases in non-obese diabetic mice . Additionally, we found that lower levels of H2S are not confined to the circulation in the setting of diabetes, as evidenced by the findings that cardiac levels of H2S were also decreased in db/db diabetic mice. On the basis of this evidence, one can speculate that decreased H2S levels contribute to the pathophysiology of diabetes . This postulate is further supported by the findings that restoring H2S levels in the setting of diabetes protects against myocardial infarction, cardiomyopathy and vascular dysfunction in models of STZ-induced diabetes -. Clinically, the negative association between diabetes and H2S also exists, as evidenced by the findings that lower circulating H2S levels are detected in plasma samples taken from patients with T2DM ,. Therefore, strategies designed to restore H2S levels have the potential to be used as adjuvant therapy to provide beneficial effects against the cardiovascular complications associated with diabetes.
To date, the vast majority of research studies investigating the cardioprotective effects of H2S in models of acute MI/R injury have been conducted in non-diabetic animals. Therefore, the purpose of this study was to determine if H2S therapy given at the time of reperfusion could provide cardioprotection in the setting of diabetes using a well-established in vivo mouse model of MI/R injury.
Male non-diabetic (C57BLKS/J) and diabetic (BKS.Cg-Dock7M+/+Leprdb/J mice; Jackson Labs, Bar Harbor, ME) were utilized at 12 weeks of age. All experimental mouse procedures were approved by the Institute for Animal Care and Use Committee at Emory University School of Medicine and conformed to the Guide for the Care and Use of Laboratory Animals, published by the National Institutes of Health (NIH Publication No. 86-23, Revised 1996) and with federal and state regulations.
Sodium Sulfide (Na2S; Sigma Aldrich. USA; catalog# 407410) was dissolved in saline and administered using a 32-gauge needle at doses ranging from 0.05 to 1 mg/kg in a final volume of 50 μL as a single injection directly into the lumen of the left ventricle at the time of reperfusion. Saline was administered in the same manner for the respective vehicle groups. In all cases, the Na2S was prepared just prior to use. Groups of mice also received 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene (U0126; 0.1 mg/kg).
Blood glucose determination
Blood obtained via a tail snip was screened using a Xtra glucose-monitoring system (Precision).
Myocardial ischemia-reperfusion protocol and myocardial injury assessment
Surgical ligation of the left coronary artery (LCA) myocardial infarct size determination, and Troponin-I measurements were performed similar to methods described previously .
The degree of lipid peroxidation was determined by evaluating the levels of malondialdehyde (MDA) in heart tissue using a commercially available thiobarbituric acid reactive substances (TBARS) assay kit according to the manufacture’s instructions (Enzo Life Sciences; catalog# ALX-850-287-KI01).
Western blot analysis
Samples of the heart were homogenized to obtain whole cell fractions. Equal amounts of protein were loaded into lanes of polyacrylamide-SDS gels and Western blot analysis was performed as previously described .
The activity of Caspase-3 was measured in heart homogenates using a commercially available assay kit according to the manufacture’s instructions (abcam; catalog# ab39401).
All data in this study are expressed as mean ± standard error (SEM). Differences in data between the groups were compared using Prism 4 (GraphPad Software, Inc) with Student’s paired 2-tailed t test or one-way analysis of variance (ANOVA). For the one-way ANOVA, if a significant variance was found, the Tukey test was used as the post hoc analysis. A p value less than 0.05 was considered significant.
Diabetes increases injury following MI/R
Body weights and blood glucose levels
24.3 ± 0.9
154.1 ± 3.1
47.1 ± 0.7***
544.1 ± 19.9***
Diabetic + Na2S (0.05 mg/kg)
45.5 ± 1.3***
531.6 ± 40.9***
Diabetic + Na2S (0.1 mg/kg)
46.3 ± 1.2***
581.1 ± 29.5***
Diabetic + Na2S (0. 5 mg/kg)
48.2 ± 1.6***
536.2 ± 22.8***
Diabetic + Na2S (1 mg/kg)
50.2 ± 1.8***
554.0 ± 34.1***
Diabetic + Na2S (0.1 mg/kg, 24 hr rep)
49.9 ± 1.1***
551.1 ± 36.9***
Na2S dose-dependently reduces injury in diabetic mice following MI/R
To investigate if exogenous H2S therapy limits MI/R injury in the setting of diabetes, diabetic mice were subjected to 30 minutes of ischemia and 4 hours of reperfusion. Na2S (0.05 to 1 mg/kg) or vehicle was administered at the time of reperfusion via a direct injection into the LV lumen. Na2S dose-dependently reduced myocardial INF/AAR (Figure 1C). A dose of 0.1 mg/kg was found to be the most protective with a 22% reduction in INF/AAR (72.2 ± 2.9 for vehicle vs. 56.0 ± 3.0 for Na2S 0.1 mg/kg, p < 0.01). Na2S also reduced circulating levels of troponin-I in a dose dependent manner (Figure 1D). In separate experiments, additional groups of mice were subjected to 30 minutes of ischemia and 24 hours of reperfusion. Analogous to the earlier findings, mice receiving Na2S (0.1 mg/kg) displayed a 20% reduction in INF/AAR as compared with vehicle-treated mice (Figure 1E). Body weight and blood glucose levels taken prior to ischemia are shown in the Table 1.
The reduction in myocardial injury induced by Na2S is associated with a reduction in apoptosis and oxidative stress
Na2S Therapy activated the Erk1/2 Arm of the RISK pathway
Na2S Therapy inhibited GSK3β
Inhibition of Erk1/2 signaling attenuated the infarct sparing effects of Na2S therapy
Akt Signaling is not activated by ischemia nor Na2S therapy
The main findings of this study are the following: 1) Na2S therapy administered at the time of reperfusion reduces MI/R injury in the setting of T2DM; 2) Na2S therapy activates the Erk1/2 arm of the RISK pathway; 3) Erk1/2 signaling increases anti-apoptotic proteins and inhibits the activation of GSK3β 4) Na2S therapy provides it’s infarct sparing effects in an Erk1/2-dependent manner.
The previous studies investigating the cardioprotective effects of H2S have provided important mechanistic insights into its cytoprotective actions . However, these studies have offered very little insights into the ability of H2S to protect in the setting of a diseased state, such as diabetes. As such, the results of the current study are the first to demonstrate that the administration of Na2S therapy at the time of reperfusion provides cardioprotection in the setting of T2DM. In agreement with a previous study with non-diabetic mice , we found that Na2S dose-dependently reduced myocardial injury, as evidenced by a reduction in infarct size and circulating troponin-I levels. However, despite the observed cardioprotective effects of an acute administration of Na2S in the current study, we found that the magnitude of infarct size reduction was significantly less than that observed in non-diabetic mice. This suggests that the underlying pathology present in the setting of T2DM may impair critical cardioprotective signaling and may minimize the therapeutic benefit of pharmacological agents. However, these results are of clinical relevance since they demonstrate that H2S treatment can potentially be initiated at the time of coronary artery reperfusion to diabetic patients experiencing myocardial ischemia in an effort to reduce myocardial infarction.
One of the major therapeutic targets for protection against MI/R injury is the activation of the RISK pathway. As noted above, the RISK pathway is a term given to a signaling cascade involving prosurvival kinases, which confer cardioprotection when specifically activated at the onset of reperfusion following myocardial ischemia. The original members reported to be a part of the RISK pathway were the phosphatidylinositol-3 kinase (PI3K), Akt, and extracellular regulated kinase 1/2 (Erk1/2). Additional studies have expanded this list to include other kinases such as protein kinase C (PKC; primarily the PKC-ε isoform), protein kinase G (PKG), and glycogen synthase kinase 3β (GSK-3β) ,. It has been suggested that targeting the RISK pathway with pharmacological agents may be a viable treatment option for MI/R injury. For instance, it has now been demonstrated in preclinical models that insulin, urocortin, atorvastatin, bradykinin, opioid receptor agonists, atrial natriuretic peptide (ANP), and Glucagon-Like Peptide-1, reduce myocardial infarct size when administered at the time of myocardial reperfusion through the activation of the RISK pathway . Importantly, it has also been demonstrated that ANP reduced infarct size, improved left ventricular function, and lowered combined end-point of death or cardiac failure when administered to patients undergoing primary percutaneous coronary intervention .
Mitochondria are essential for cell survival, both because of their role as metabolic energy producers and as regulators of programmed cell death . Under normal conditions, the mitochondrial network of the myocyte must have properties of both constancy and flexibility, first providing a steady supply of ATP to fuel contraction, and second, to adapt the rate of energy production to meet the changing metabolic demand as workload varies . The mitochondrial permeability transition pore (mPTP) occupies a fundamental role in determining cellular survival in the setting of myocardial ischemia-reperfusion injury because MPTP opening also causes mitochondrial membrane potential (ΔΨ m) depolarization . Early reperfusion following ischemia represents a period when ΔΨ m is most likely to become unstable due to the production of high levels of ROS and ensuing oxidative stress. As a result, the loss of ΔΨ m during this time causes a rapid impairment of mitochondrial function, which ultimately leads to apoptotic cell death through the release of pro-apoptotic proteins or can initiate necrotic cell death. Thus, maintaining ΔΨ m is of paramount importance during the period of early reperfusion, as it is a major determinant of cell fate following ischemia . Given, that mitochondria lie at the core of existence of cellular life, it is of no surprise that they are the most common effector for numerous cardioprotective-signaling cascades. Importantly, a common target of the signaling activated by the RISK pathway is the mitochondria. Specifically, activation of the RISK pathway has been shown to inhibit the opening of the mPTP , thereby preventing apoptotic death caused by mitochondrial membrane permeabilitization .
While the downstream effectors of the RISK pathway have not been fully elucidated, the Erk1/2 signaling arm has been shown to signal through signal transducer and activator of transcription 3 (STAT-3), p90RSK, Bcl-2, Bcl-xL, and HSPs ,,. Erk1/2 dependent p90Rsk activation is essential to providing protection against reperfusion therapy because active p90RSK phosphorylates and inhibits the pro-apoptotic protein BAD . This is important, because when BAD is active it binds to BCL-xL and disrupts the BCL-xL/Bax complex causing the accumulation of Bax in the mitochondrial membrane, which results in apoptosis. Additionally, Erk1/2 dependent p90Rsk activation also suppresses the opening of the mPTP by inhibiting GSK3β . It is already known that the diabetic state impairs the activation of the RISK pathway in the setting of MI/R. In a type 1 diabetic rat model (streptozotocin-induced), erythropoietin (EPO)-induced cardioprotection through RISK signaling was lost . Interestingly in the same study, EPO-induced cardioprotection through RISK signaling was still maintained in high fat diet (HFD)-induced insulin resistant mice suggesting that it remains unclear how different forms of diabetes and insulin resistance are affecting the activation of the RISK pathway in response to MI/R. For this reason alone it is very important to investigate how the T2DM state would affect RISK signaling and whether Na2S therapy would influence the RISK pathway in this model. In our previous paper we showed that 7 days of Na2S treatment in a preconditioned state can activate Erk1/2 , and because Erk1/2 is an important part of providing protection in the early reperfusion state we wanted to see if Na2S could activate Erk1/2 when it was administered at the time of reperfusion. The findings of the current study agree with many others that the diabetic state impairs the RISK pathway. Specifically, MI/R injury failed to activate Erk1/2 signaling in untreated mice. This was further associated with the activation of Bad and GSK3β. Based on the evidence that MI/R activates Erk1/2 signaling in non-diabetic animals , it can be suggested that impaired signaling in the Erk1/2 arm of the RISK pathway contributes in part to the enhanced injury observed in the db/db diabetic heart. Importantly, our findings indicate that Na2S therapy is able to provide protection against MI/R injury through its ability to activate Erk1/2 signaling during early reperfusion. Moreover, our findings suggest that the activation of Erk1/2 signaling and subsequent activation of p90RSK, inhibition of Bad, and inhibition of GSK3β are responsible for the anti-apoptotic and infarct lowering effects of Na2S therapy.
Another important finding of the study relates to the other arm of the RISK pathway: Akt pathway. Specifically, our data suggests that Akt is not activated in the db/db heart by ischemia-reperfusion injury nor Na2S therapy. The former is supported by previous data indicating that Akt is not activated by myocardial ischemia in the db/db heart and likely reflects an impairment in pro-survival signaling induced by diabetes. The latter is in contrast to previous findings by our group demonstrating that H2S therapy activates Akt in the setting of heart failure . It is important to note that our previous study used non-diabetic mice and evaluated the activation of Akt in response to pressure-overload heart failure. Additionally, we evaluated the activation of Akt 6 weeks after the induction of heart failure. Therefore, it is possible that Na2S therapy could have an effect on Akt activation in the db/db heart at a different time point than the one we evaluated (i.e. 30 minutes of reperfusion or 24 hours of reperfusion). As such, future studies are necessary to determine the role Akt plays in mediating the cardioprotective effects of H2S therapy in the setting of type-2 diabetes.
Although the current study demonstrates that a single administration of Na2S therapy is able to reduce infarction in the setting of MI/R injury, there are some limitations that need to be noted. Because a mouse model was used, these data may not accurately predict human disease. Therefore, future studies need to be conducted in large animal models that are more clinically relevant. Another limitation is that we did not evaluate why T2DM impairs the RISK pathway during the early reperfusion period following myocardial ischemia. Future studies are definitely warranted to delve further into the mechanism(s) responsible for this impairment. Additionally, further studies are needed to evaluate how Na2S therapy affects the permeability of the mPTP in the diabetic state following MI/R injury.
In summary, our findings demonstrate for the first time that exogenous administration of Na2S attenuates MI/R injury in diabetic animals when administered at the time of reperfusion. This is important because it confirms the potential therapeutic effects of H2S in treating a heart attack in the setting of diabetes. It also highlights the complexity of therapeutic intervention for the diabetic heart following ischemia, as even at its most protective dose, the robust cardioprotective effects of Na2S that have previously been reported in the non-diabetic state were diminished in the diabetic heart.
Sources of funding
Supported by a grant the National Institutes of Health National Heart Lung and Blood Institute (5R01HL098481-05) to J.W.C. This work was also supported by funding from the Carlyle Fraser Heart Center of Emory University Hospital Midtown.
- Nathan DM: Long-term complications of diabetes mellitus. N Engl J Med. 1993, 328: 1676-1685. 10.1056/NEJM199306103282306.View ArticlePubMedGoogle Scholar
- Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG: Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol. 1993, 22: 1788-1794. 10.1016/0735-1097(93)90758-S.View ArticlePubMedGoogle Scholar
- Rennert G, Saltz-Rennert H, Wanderman K, Weitzman S: Size of acute myocardial infarcts in patients with diabetes mellitus. Am J Cardiol. 1985, 55: 1629-1630. 10.1016/0002-9149(85)90988-9.View ArticlePubMedGoogle Scholar
- Jay D, Hitomi H, Griendling KK: Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med. 2006, 40: 183-192. 10.1016/j.freeradbiomed.2005.06.018.View ArticlePubMedGoogle Scholar
- Doeller JE, Isbell TS, Benavides G, Koenitzer J, Patel H, Patel RP, Lancaster JR, Darley-Usmar VM, Kraus DW: Polarographic measurement of hydrogen sulfide production and consumption by mammalian tissues. Anal Biochem. 2005, 341: 40-51. 10.1016/j.ab.2005.03.024.View ArticlePubMedGoogle Scholar
- Szabo C: Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov. 2007, 6: 917-935. 10.1038/nrd2425.View ArticlePubMedGoogle Scholar
- Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, Jiao X, Scalia R, Kiss L, Szabo C, Kimura H, Chow CW, Lefer DJ: Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci U S A. 2007, 104: 15560-15565. 10.1073/pnas.0705891104.PubMed CentralView ArticlePubMedGoogle Scholar
- Calvert JW, Elston M, Nicholson CK, Gundewar S, Jha S, Elrod JW, Ramachandran A, Lefer DJ: Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice. Circulation. 2010, 122: 11-19. 10.1161/CIRCULATIONAHA.109.920991.PubMed CentralView ArticlePubMedGoogle Scholar
- Calvert JW, Jha S, Gundewar S, Elrod JW, Ramachandran A, Pattillo CB, Kevil CG, Lefer DJ: Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. Circ Res. 2009, 105: 365-374. 10.1161/CIRCRESAHA.109.199919.PubMed CentralView ArticlePubMedGoogle Scholar
- Nicholson CK, Lambert JP, Molkentin JD, Sadoshima J, Calvert JW: Thioredoxin 1 is essential for sodium sulfide-mediated cardioprotection in the setting of heart failure. Arterioscler Thromb Vasc Biol. 2013, 33: 744-751. 10.1161/ATVBAHA.112.300484.View ArticlePubMedGoogle Scholar
- Polhemus DJ, Kondo K, Bhushan S, Bir SC, Kevil CG, Murohara T, Lefer DJ, Calvert JW: Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis. Circ Heart Fail. 2013, 6: 1077-1086. 10.1161/CIRCHEARTFAILURE.113.000299.View ArticlePubMedGoogle Scholar
- Kondo K, Bhushan S, King AL, Prabhu SD, Hamid T, Koenig S, Murohara T, Predmore BL, Gojon G, Gojon G, Wang R, Karusula N, Nicholson CK, Calvert JW, Lefer DJ: H(2)S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase. Circulation. 2013, 127: 1116-1127. 10.1161/CIRCULATIONAHA.112.000855.PubMed CentralView ArticlePubMedGoogle Scholar
- Givvimani S, Munjal C, Gargoum R, Sen U, Tyagi N, Vacek JC, Tyagi SC: Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure. J Appl Physiol. 2011, 110: 1093-1100. 10.1152/japplphysiol.01064.2010.PubMed CentralView ArticlePubMedGoogle Scholar
- Mishra PK, Tyagi N, Sen U, Givvimani S, Tyagi SC: H2S ameliorates oxidative and proteolytic stresses and protects the heart against adverse remodeling in chronic heart failure. Am J Physiol Heart Circ Physiol. 2010, 298: H451-H456. 10.1152/ajpheart.00682.2009.PubMed CentralView ArticlePubMedGoogle Scholar
- Calvert JW, Coetzee WA, Lefer DJ: Novel insights into hydrogen sulfide–mediated cytoprotection. Antioxid Redox Signal. 2010, 12: 1203-1217. 10.1089/ars.2009.2882.PubMed CentralView ArticlePubMedGoogle Scholar
- Whiteman M, Gooding KM, Whatmore JL, Ball CI, Mawson D, Skinner K, Tooke JE, Shore AC: Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide. Diabetologia. 2010, 53: 1722-1726. 10.1007/s00125-010-1761-5.View ArticlePubMedGoogle Scholar
- Yusuf M, Kwong Huat BT, Hsu A, Whiteman M, Bhatia M, Moore PK: Streptozotocin-induced diabetes in the rat is associated with enhanced tissue hydrogen sulfide biosynthesis. Biochem Biophys Res Commun. 2005, 333: 1146-1152. 10.1016/j.bbrc.2005.06.021.View ArticlePubMedGoogle Scholar
- Brancaleone V, Roviezzo F, Vellecco V, De Gruttola L, Bucci M, Cirino G: Biosynthesis of H2S is impaired in non-obese diabetic (NOD) mice. Br J Pharmacol. 2008, 155: 673-680. 10.1038/bjp.2008.296.PubMed CentralView ArticlePubMedGoogle Scholar
- Szabo C: Roles of hydrogen sulfide in the pathogenesis of diabetes mellitus and its complications. Antioxid Redox Signal. 2012, 17: 68-80. 10.1089/ars.2011.4451.View ArticlePubMedGoogle Scholar
- Peake BF, Nicholson CK, Lambert JP, Hood RL, Amin H, Amin S, Calvert JW: Hydrogen sulfide preconditions the db/db diabetic mouse heart against ischemia-reperfusion injury by activating Nrf2 signaling in an Erk-dependent manner. Am J Physiol Heart Circ Physiol. 2013, 304: H1215-H1224. 10.1152/ajpheart.00796.2012.PubMed CentralView ArticlePubMedGoogle Scholar
- El-Seweidy MM, Sadik NA, Shaker OG: Role of sulfurous mineral water and sodium hydrosulfide as potent inhibitors of fibrosis in the heart of diabetic rats. Arch Biochem Biophys. 2011, 506: 48-57. 10.1016/j.abb.2010.10.014.View ArticlePubMedGoogle Scholar
- Suzuki K, Olah G, Modis K, Coletta C, Kulp G, Gero D, Szoleczky P, Chang T, Zhou Z, Wu L, Wang R, Papapetropoulos A, Szabo C: Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function . Proc Natl Acad Sci U S A. 2011, 108: 13829-13834. 10.1073/pnas.1105121108.PubMed CentralView ArticlePubMedGoogle Scholar
- Jain SK, Bull R, Rains JL, Bass PF, Levine SN, Reddy S, McVie R, Bocchini JA: Low levels of hydrogen sulfide in the blood of diabetes patients and streptozotocin-treated rats causes vascular inflammation?. Antioxid Redox Signal. 2010, 12: 1333-1337. 10.1089/ars.2009.2956.PubMed CentralView ArticlePubMedGoogle Scholar
- Hausenloy DJ, Yellon DM: Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev. 2007, 12: 217-234. 10.1007/s10741-007-9026-1.View ArticlePubMedGoogle Scholar
- Yellon DM, Baxter GF: Reperfusion injury revisited: is there a role for growth factor signaling in limiting lethal reperfusion injury?. Trends Cardiovasc Med. 1999, 9: 245-249. 10.1016/S1050-1738(00)00029-3.View ArticlePubMedGoogle Scholar
- Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanot S, Watanabe K, Fukuzawa S, Hirayama A, Nakamura N, Kimura K, Fujii K, Ishihara M, Saito Y, Tomoike H, Kitamura S: Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007, 370: 1483-1493. 10.1016/S0140-6736(07)61634-1.View ArticlePubMedGoogle Scholar
- Duchen MR: Roles of mitochondria in health and disease. Diabetes. 2004, 53 (Suppl 1): S96-S102. 10.2337/diabetes.53.2007.S96.View ArticlePubMedGoogle Scholar
- Aon MA, Cortassa S, Akar FG, O’Rourke B: Mitochondrial criticality: a new concept at the turning point of life or death. Biochim Biophys Acta. 2006, 1762: 232-240. 10.1016/j.bbadis.2005.06.008.PubMed CentralView ArticlePubMedGoogle Scholar
- Churchill EN, Mochly-Rosen D: The roles of PKCdelta and epsilon isoenzymes in the regulation of myocardial ischaemia/reperfusion injury. Biochem Soc Trans. 2007, 35: 1040-1042. 10.1042/BST0351040.View ArticlePubMedGoogle Scholar
- Davidson SM, Hausenloy D, Duchen MR, Yellon DM: Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol. 2006, 38: 414-419. 10.1016/j.biocel.2005.09.017.View ArticlePubMedGoogle Scholar
- Boengler K, Schulz R, Heusch G: Loss of cardioprotection with ageing. Cardiovasc Res. 2009, 83: 247-261. 10.1093/cvr/cvp033.View ArticlePubMedGoogle Scholar
- Meng XB, Sun GB, Wang M, Sun J, Qin M, Sun XB: P90RSK and Nrf2 Activation via MEK1/2-ERK1/2 Pathways Mediated by Notoginsenoside R2 to Prevent 6-Hydroxydopamine-Induced Apoptotic Death in SH-SY5Y Cells. Evid Based Complement Alternat Med. 2013, 2013: 971712-PubMed CentralPubMedGoogle Scholar
- Ghaboura N, Tamareille S, Ducluzeau PH, Grimaud L, Loufrani L, Croue A, Tourmen Y, Henrion D, Furber A, Prunier F: Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3beta signaling. Basic Res Cardiol. 2011, 106: 147-162. 10.1007/s00395-010-0130-3.View ArticlePubMedGoogle Scholar
- Li DY, Tao L, Liu H, Christopher TA, Lopez BL, Ma XL: Role of ERK1/2 in the anti-apoptotic and cardioprotective effects of nitric oxide after myocardial ischemia and reperfusion. Apoptosis. 2006, 11: 923-930. 10.1007/s10495-006-6305-6.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.